Jump to content

Annie Luetkemeyer

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 107.196.237.244 (talk) at 22:59, 19 October 2023. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Annie Luetkemeyer
Luetkemeyer in 2021
Born
Annie F. Luetkemeyer

Baltimore, Maryland U.S.
NationalityUSA
EducationStanford University
Harvard Medical School
OccupationInfectious diseases researcher
Years active1999–present
RelativesJulie Bowen (sister)

Annie F. Luetkemeyer is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis.[1] During the COVID-19 pandemic Luetkemeyer led a clinical trial of remdesivir. She has also researched treatment of COVID-19 as a co-infection with HIV.

Early life and education

Luetkemeyer was born in Baltimore, Maryland, to Suzanne Luetkemeyer (née Frey) and John Alexander Luetkemeyer Jr., a commercial real estate developer. She is the youngest of three sisters, one of whom is actress Julie Bowen. She grew up in Ruxton-Riderwood, Maryland.[2] In 1984, Luetkemeyer graduated from the Calvert School.[3]

In 1994, Luetkemeyer received an AB with distinction in American Studies from Stanford University.[4] In 1999, she received an M.D. in medicine from Harvard Medical School.[5] In 2002 and 2003, Luetkemeyer trained in internal medicine at the University of California, San Francisco. In 2006, she completed advance training in clinical research there, and then an infectious disease fellowship in 2007.[5]

Career

In 2012 Luetkemeyer called for investigations into the doses of medications used for the treatment of HIV infection and tuberculosis.[6] The Food and Drug Administration had rewritten the recommendations in 2012. In a series of small studies in Europe it had been shown that rifampicin, a drug used to treat tuberculosis, could limit the effectiveness of efavirenz, a drug used to treat HIV. The drugs interact through a liver enzyme (cytochrome P450) that is produced at elevated levels in patients who take rifampicin, and breaks down the efavirenz. To overcome this, the 2012 FDA recommendations proposed larger doses of efavirenz. Luetkemeyer argued that the recommendations were not appropriate for all populations in the United States, and could result in more drug toxicity.[6] She showed that increasing the dosage of efavirenz may cause more side effects—as well as coming at a greater financial cost.[6]

Dr Annie Luetkemeyer in 2021

During the COVID-19 pandemic, Luetkemeyer led investigations into potential therapies for the disease.[7][8] She is a member of the UCSF cross-campus COVID-19 task force.[9] In line with most official advice, Luetkemeyer called for older people and those with preexisting conditions to be more careful during the outbreak, as the virus "taxes all organ systems".[10] She studied which COVID-19 patients were most likely to benefit from treatment, when during the illness was the best time for treatment, and which types of treatment (antivirals or anti-inflammatories) were most appropriate. She has also outlined what pre- and post-exposure prophylaxis healthcare workers and household contacts can do to prevent disease spread. Luetkemeyer has called for more randomized controlled trials to assess the impact of hydroxychloroquine.[11] She is leading a clinical trial of the drug remdesivir.[12][13] The San Francisco General Hospital SARS-CoV-2 guidelines recommend treatment only if patients are hospitalized or have strong risk factors for progression into severe disease. As of March 2020, the guidelines included remdesivir, or hydroxychloroquine if remdesivir was not feasible.[needs update]

Selected works and publications

Scholia has an author profile for Annie Luetkemeyer.

References

  1. ^ Luetkemeyer, Annie (August 2, 2016). "Hepatitis C is Curable". KQED.
  2. ^ Marbella, Jean (September 12, 2010). "Julie Bowen's modern life". The Baltimore Sun.
  3. ^ "The Illustrious Luetkemeyer Girls". Reflections 2012. XIX (1). Calvert School: 16–19. Fall 2012.
  4. ^ "Anne F. Luetkemeyer, MD". IAS-USA. Retrieved April 15, 2020.
  5. ^ a b "Annie Luetkemeyer | UCSF Profiles". profiles.ucsf.edu. Retrieved April 15, 2020.
  6. ^ a b c Bardi, Jason (July 23, 2012). "UCSF/SFGH Researchers Call for Change in New FDA Recommendation on HIV and TB Drug Doses". University of California, San Francisco.
  7. ^ Wachter, Robert; Luetkemeyer, Annie (March 15, 2020). "Treatment options for COVID-19: Dr. Annie Luetkemeyer". The Hospitalist.
  8. ^ Kupferschmidt, Kai (April 7, 2020). "Trials of drugs to prevent coronavirus infection begin in health care workers". Science | AAAS. Retrieved April 15, 2020.
  9. ^ "About the Cross-campus Infectious Disease COVID-19 Task Force | HIV, ID and Global Medicine". hividgm.ucsf.edu. Retrieved April 20, 2020.
  10. ^ Hafner, Katie (March 14, 2020). "How to Protect Older People From the Coronavirus". The New York Times.
  11. ^ "What scientists do and don't know about treating coronavirus". National Geographic. March 25, 2020. Retrieved April 15, 2020.
  12. ^ "UCSF's noon grand rounds: A slow reopening, racial disparities and no quick remedies". Mission Local. April 17, 2020. Retrieved April 19, 2020.
  13. ^ "Anti-viral Remdesivir, Wall Street's darling, may not even work against COVID-19". Mission Local. April 18, 2020. Retrieved April 19, 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Annie_Luetkemeyer&oldid=1180959822"